Compare Stocks → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVEONASDAQ:BLPHNASDAQ:ORMPNASDAQ:SESNNASDAQ:TORC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$670K0.6722,748 shs2,320 shsORMPOramed Pharmaceuticals$2.33+2.6%$2.89$1.67▼$5.25$91.98M1.81125,111 shs59,020 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsTORCresTORbio$2.00+2.6%$12.16$0.86▼$10.50$72.91M2.431.15 million shs303,289 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BLPHBellerophon Therapeutics-6.07%-10.43%-7.09%-15.47%-99.49%ORMPOramed Pharmaceuticals+2.64%-3.72%-19.93%+1.75%+1.30%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%TORCresTORbio+2.56%-9.09%-8.68%-19.35%-67.64%Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new reportMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLPHBellerophon Therapeutics2.092 of 5 stars3.00.00.04.83.20.00.6ORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO PharmaceuticalsN/AN/AN/AN/ABLPHBellerophon Therapeutics2.00Hold$2.003,813.89% UpsideORMPOramed PharmaceuticalsN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28BLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AORMPOramed Pharmaceuticals$1.34M70.46N/AN/A$4.04 per share0.58SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ABLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)ORMPOramed Pharmaceuticals$5.53M$0.1416.64∞N/AN/A-7.15%-5.70%5/9/2024 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ATORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/ALatest BLPH, AVEO, ORMP, SESN, and TORC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/23/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A3/6/2024Q4 2023ORMPOramed Pharmaceuticals-$0.12-$0.08+$0.04-$0.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35BLPHBellerophon TherapeuticsN/A3.963.96ORMPOramed PharmaceuticalsN/A3.063.06SESNSesen BioN/A6.106.10TORCresTORbioN/A20.6920.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%BLPHBellerophon Therapeutics10.61%ORMPOramed Pharmaceuticals12.73%SESNSesen Bio16.45%TORCresTORbio46.19%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%BLPHBellerophon Therapeutics5.20%ORMPOramed Pharmaceuticals12.00%SESNSesen Bio3.20%TORCresTORbio11.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableTORCresTORbioN/A36.45 millionN/ANot OptionableBLPH, AVEO, ORMP, SESN, and TORC HeadlinesSourceHeadlineAdicet Bio Inc (ACET)investing.com - January 30 at 1:54 PMTargeting the biology of aging with mTOR inhibitors - Nature.comnews.google.com - May 4 at 10:20 PMPARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLivenews.google.com - March 17 at 7:14 PMMichelle Chaka Joins Torc as Senior Vice President, Safety and Regulatoryfinance.yahoo.com - February 24 at 7:08 PMTorc names regulatory, safety SVPvirginiabusiness.com - February 24 at 7:08 PMGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRnews.google.com - February 8 at 10:13 AMPhenotypic Presentations and the Management of Moderate to ... - Healionews.google.com - January 31 at 2:37 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comnews.google.com - January 23 at 3:41 PMAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswirenews.google.com - January 23 at 8:44 AMTinOne Resources Inc. (TORC.V)finance.yahoo.com - January 10 at 8:39 AMresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities Newsnews.google.com - December 16 at 11:48 PMresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities Newsnews.google.com - December 12 at 10:01 PMBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technologynews.google.com - November 3 at 9:25 PMTORC Investments, LLCgwinnettdailypost.com - October 6 at 9:57 AMCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbesforbes.com - September 19 at 2:52 PMFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journalsbizjournals.com - September 12 at 7:31 PMCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRopenpr.com - September 6 at 7:33 AMFor preventing aging, some decades old drugs? - BioWorld Onlinebioworld.com - July 18 at 10:42 PMForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comstreetinsider.com - July 8 at 2:10 AMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comgurufocus.com - June 21 at 9:11 PMThe Best Hand Creams - Don't Waste Your Moneydontwasteyourmoney.com - June 18 at 1:34 PMTime Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints Newsendpts.com - June 3 at 11:42 PMTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TVkulr8.com - June 3 at 11:42 PMTerns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comstreetinsider.com - June 1 at 9:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.resTORbioNASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.